Lyme disease vaccine candidate has the potential to provide protection against most Borrelia species
November 27, 2014
European biotechnology company Valneva SE (Valneva) announced today that an article, presenting for the first time the preclinical data of its novel vaccine candidate for prevention of Lyme borreliosis, was published in PLOS ONE, the largest scientific journal in the world by volume.
The publication reveals that Valneva’s vaccine candidate, a multivalent, protein subunit based vaccine, has the potential to provide protection against the majority of Borrelia species pathogenic for humans. Lyme borreliosis is caused by at least four species of Borrelia and is transmitted via the bite of an infected tick.
Lees meer Bron: OutbreakNewsToday
Design and Development of a Novel Vaccine for Protection against Lyme Borreliosis
Pär Comstedt, Markus Hanner, Wolfgang Schüler, Andreas Meinke, Urban Lundberg
Published: November 19, 2014 •DOI: 10.1371/journal.pone.0113294
There is currently no Lyme borreliosis vaccine available for humans, although it has been shown that the disease can be prevented by immunization with an OspA-based vaccine (LYMErix). Outer surface protein A (OspA) is one of the dominant antigens expressed by the spirochetes when present in a tick. The Borrelia species causing Lyme borreliosis in Europe express different OspA serotypes on their surface, B. burgdorferi (serotype 1), B. afzelii (serotype 2), B. garinii (serotypes, 3, 5 and 6) and B. bavariensis (serotype 4), while only B. burgdorferi is present in the US. In order to target all these pathogenic Borrelia species, we have designed a multivalent OspA-based vaccine.
Lees meer Bron: PLOS ONE